Orchid Pharma share price
You have to be logged in to add this to Watchlist.- ₹858.75(6.72%)November 17, 2025 14:50:45 PM IST
- NSE
- BSE
- Vol : 267.30K (NSE + BSE)Last 20 day avg : 162.16 K
Orchid Pharma is trading 6.72% upper at Rs 858.75 as compared to its last closing price. Orchid Pharma has been trading in the price range of 869.40 & 810.00. Orchid Pharma has given -55.52% in this year & -4.50% in the last 5 days. Orchid Pharma has TTM P/E ratio 68.10 as compared to the sector P/E of 28.85.There are 3 analysts who have initiated coverage on Orchid Pharma. There are 2 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of -5.72 Crores in its last quarter.Listed peers of Orchid Pharma include Rpg Life Sciences (1.42%), Dishman Carbogen Amcis (-0.14%), Orchid Pharma (6.72%).The Mutual Fund holding in Orchid Pharma was at 18.04% in 30 Sep 2025. The MF holding has decreased from the last quarter. The FII holding in Orchid Pharma was at 1.56% in 30 Sep 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Nov 17, 2025, 09:21 AM UTC
- BetaHigh volatility3.01Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.14The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BHigher than historical values3.19The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is not profitable- The company's revenue fell during September quarter by 13.10% from Rs 222.70 crore to Rs 193.52 crore, year-on-year
- Company has registered a loss of 5.72 cr vs a profit of 27.24 cr in the same quarter last year.
- The debt to equity of the company is higher than the industry median
Company can comfortably pay off its interest obligations with its earnings
- R1
- 851.07
- R2
- 933.48
- R3
- 999.02
- S1
- 703.12
- S2
- 637.58
- S3
- 555.17
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Rpg Life Sciences | Moderately Bearish | 2,319.55 | 1.42 | 3,836.31 | 35.28 | 7.8 | 0.80 | - |
| Dishman Carbogen Amcis | Moderately Bearish | 248.75 | -0.14 | 3,924.40 | 232.91 | 0.69 | - | 23.83 |
| Orchid Pharma | Bullish | 858.75 | 6.72 | 4,343.09 | 38.04 | 2.99 | - | 10.39 |
| Advanced Enzyme Technologies | Bullish | 336.80 | 1.74 | 3,747.62 | 28.86 | 2.66 | 1.54 | 1.47 |
| Morepen Laboratories | Bearish | 46.45 | -0.11 | 2,545.24 | 29.06 | 3.03 | - | 3.39 |
- Promoter(s) holds a high stake in the company at 69.84%
- FIIs are invested in this company
- FIIs holding has increased by 0.17 percentage points from previous quarter
- Mutual Funds holding has decreased by 0.54 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-11-11 | Quarterly Results |
| 2025-08-12 | Quarterly Results |
| 2025-05-26 | Audited Results |
| 2025-02-12 | Quarterly Results |
| 2024-11-11 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE191A01027
- BSE Code524372
- NSE CodeORCHPHARMA
Orchid Pharma is trading at 858.75 as on Mon Nov 17 2025 09:20:45. This is 6.72% upper as compared to its previous closing price of 804.70.
The market capitalization of Orchid Pharma is 4343.09 Cr as on Mon Nov 17 2025 09:20:45.
The average broker rating on Orchid Pharma is Strong Buy. The breakup of analyst rating is given below -
- 2 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Orchid Pharma is 1998.00 whereas the 52 wk low is 603.80
Orchid Pharma can be analyzed on the following key metrics -
- TTM P/E: 68.10
- Sector P/E: 28.85
- Dividend Yield: 0.00%
- D/E ratio: 0.22
Orchid Pharma reported a net profit of 99.66 Cr in 2025.
The Mutual Fund Shareholding was 18.04% at the end of 30 Sep 2025.